Mergers & Acquisitions ·
Telix Reports Q3 Revenue of US$245M and Announces US$1.65B Merger with ITM
TLXTelix Pharmaceuticals Ltd
Telix Pharmaceuticals reported third-quarter revenue of US$245 million, a 19% increase year-over-year, driven by strong demand for its commercial portfolio. The company also announced a transformative merger with Isotope Technologies Munich SE (ITM), involving upfront consideration of US$1.65 billion and contingent payments up to US$700 million. Additionally, Telix received FDA approval for Pixclara for glioma imaging and revised its full-year R&D expenditure guidance to US$240–260 million. Telix Pharmaceuticals is a commercial-stage global radiopharmaceutical company advancing targeted theranostics for cancer treatment.